Fulcrum Therapeutics reports promising late-stage data for sickle cell drug pociredir, with notable hemoglobin improvements.

Oregon will initially focus on providing lower-cost therapies for people living with sickle cell disease, a genetic blood ...

After decades of excruciating pain, a breakthrough sickle cell disease treatment made all the difference for one patient.

Gene Therapy Market Gene therapy market surges on breakthroughs in genome editing, rising chronic & genetic disease cases, regulatory appro ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals ...

A groundbreaking new medical dataset is poised to revolutionize health care in Africa by improving chatbots' understanding of ...

CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.

The gene editing market represents one of the most transformative sectors in modern biotechnology, fundamentally reshaping ...

The Centers for Medicare & Medicaid Services (“CMS”) recently released two proposed updates to Medicare payment rules that, if implemented, could ...

Monoclonal antibodies (mAbs) have revolutionized medicine, providing innovative treatments for many diseases. For decades, ...

In July 2025, Novartis Pharmaceuticals announced a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) ...